Core Insights - Co-Diagnostics, Inc. has regained compliance with NASDAQ listing requirements and resumed trading on March 11, 2026, enhancing its capital markets position [1] - The company is actively expanding its global presence and intellectual property, participating in Medical Korea 2026 to showcase its Co-Dx PCR point-of-care platform [2] - A new patent granted by the Japan Patent Office supports the Co-Dx PCR Pro® instrument and strengthens the company's international IP protection [3] - As of March 13, 2026, CODX stock closed at $2.80, with a market capitalization of approximately $5.87 million [4] - Co-Diagnostics is positioned as an emerging player in molecular diagnostics, focusing on clinical studies and global expansion [5] Group 1 - Co-Diagnostics has regained compliance with NASDAQ listing requirements and resumed trading on March 11, 2026, confirming compliance with the $1.00 minimum bid price rule [1] - The company will participate in Medical Korea 2026 in Seoul, South Korea, from March 19-22, 2026, showcasing its innovative diagnostic solutions [2] - The Japan Patent Office granted a patent that supports the Co-Dx PCR Pro® instrument, enhancing the company's international IP protection [3] Group 2 - CODX stock closed at $2.80 on March 13, 2026, reflecting a 3.75% increase, with a trading volume of 1,105,301 shares [4] - The company is focusing on clinical studies, regulatory pathways, and global expansion for its point-of-care technologies [5]